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Background. We and others have demonstrated that a 
low level of donor cell chimerism was present for years 
after transplantation in tissues and peripheral blood of 
heart and lung recipients; it was associated, in the latter, 
with a lower incidence of chronic rejection. To augment 
this phenomenon, we initiated a trial combining simul-
taneous infusion of donor bone marrow with heart or 
lung allotransplantation. 
Methods. Between September 1993 and January 1995, 
15 nonconditioned patients received either heart (n = 10) 
or lung (n = 5) allografts concurrent Iv with an infusion 
of unmodified donor bone marrow 13.0 x 1M~ cells/kg), 
and were maintained on an immunosuppressive regimen 
consisting of tacrolimus and steroids. 
We and others have recentlv demonstrated that a low level at donor cells was detectable in the 
peripheral blood and tissues ot long-surviving recipients 
or liver [11, kidney [2), heart [31. lung, and heart-lung Hi 
allografts. This phenomenon ot donor cell chimerism, 
which occurs bv seeding of the host's tissues with cells 
from the graft [5, 61, was associated with a lower inci-
dence or _ ~ronic rejection in tun!!; recipients [oll. To 
.lugment aonor cell chimensm, we initiated a prospective 
trial combining the simultaneous IntuslOn ot unmodified 
donor bone marrow and transplantation or heart or lung 
,lllogratts mto nonconditioned reCipients. Reported 
herein IS the outcome or the first 15 panents in this study. 
Patients and Methods 
Between Seotember 1993 and lanuarv 1995. 13 patients 
received co~bined intusion ot donor bone marrow and 
transplantation ot either heart In = ttl) or lun~ .lllogratts 
(n = 5). The mean a~e ot the recipients was ol6.3 = '::1.1 
vears Eram~eK 23 to 57 vears) with a mean tollow-up of liS 
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Results. There was no complication associated with the 
infusion of donor bone marrow. Chimerism was detect-
able in 73% of bone marrow-augmented patients up to 
the last sample tested. Of the 5 control recipients who did 
not receive bone marrow infusion. only 1 had detectable 
chimerism by flow on postoperative day 15, which dwin-
dled to an undetectable level by postoperative day 36. 
None of the patients had evidence of donor-specific 
immune modulation by mixed lymphocyte reaction. 
Conclusions. The combined infusion of donor bone 
marrow and heart or lung transplantation, without pre-
conditioning of the recipient, is safe and is associated 
with an augmentation of donor cell chimerism. 
(Ann TIiorac Surg 1995;60:1015-20> 
= 102 days. These patients, all primary transplant recip-
ients ot cadaveric organs, were not conditioned by cytoa-
blative or cytoreductive regimen before transplantation. 
Furthermore, all recipients had a panel reactive antibody 
titer of less than 10%, and none had a positive lympho-
cytotoxic crossma.tch. The mean number of HLA mis-
matches was 4.5 :: 1.2 (range, 3 to 6), with no patient 
ha\"Ulg complete HLA compatibility with the donor. 
Bone Marrow Preparation and Infusion 
Details of bone marrow preparation are described else-
where [71. Brietlv, thoracolumbar vertebrae were re-
trieved from the donor. Marrow cells from chipped-off 
cancellous bone were passivelv released into a process-
ing medium, filtered, washed. and resuspended in a 
suspension medium at a concentration of 2 x 107 cellsl 
mL The cell suspension was stored at 4°C until infusion. 
Cell viability was determined bv trypan blue dye exclu-
sion. and samples ot processed bone marrow cells were 
retained for microbial testing and routine progenitor cell 
assays. When the recipient was readv to receive bone 
marrow, a total of 3.0 x lOll unmodified cells/kg of bodv 
weight were resuspended in 200 mL of the suspension 
medium and infused over a period of 15 to 20 minutes via 
a central venous line. The bone marrow was usually 
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infused between 6 to 10 hours after revascularization of 
the transplanted organ. 
Immunosuppression 
Immunosuppression consisted of tacrolimus (FK506 [Pro-
grafl; Fujisawa USA. Deerfield, IL) and steroids, as pre-
viously described [81. During the first postoperative 
month, the dosage of tacrolimus was targeted to maintain 
whole blood trough levels of 15 to 20 ng/mL which, 
depending on the side effects and history of reiection, 
was gradually reduced to achieve levels of "5 to 15 ng/mL. 
Methylprednisolone (1 g) was given intraoperatively be-
fore revascularization of the organ. Except in the first 
heart recipient, this was followed in all other patients by 
a short course of steroid recycle starting on postoperative 
day (POD) 1 with 200 mg/day and tapering to 20 mg/day 
by POD 5. Further steroid reductions were individually 
tailored according to allograft function. Azathioprine was 
added if there was recurrent or recalcitrant rejection, or 
when renal dysfunction necessitated the administration 
of a lower than required dose of tacrolimus. Reiection 
was treated initially with steroid boluses (1 g methyl-
prednisolone/day x 3), whereas OKTI was resel'\'ed for 
steroid-resistant rejection. 
In Vitro Monitoring 
Mononuclear cells from recipients' peripheral blood 
(PBMC) were obtained preoperatively and biweeklv in 
the first postoperative month, and bimonthly thereafter 
for detection of donor cells and for immunolOgiC moni-
toring. 
Detection of Chimerism 
FLOW CYTOMETRY. For immunocytochemical staining, pri-
mary mouse-anti-human monoclonal antibodies di-
rected against the polvrnorphic epitopes of either HLA 
class I or class II (to distinguish donor from recipient 
HLA alleles) were used. These primary monoclonal an-
tibodies were labeled by either fluorescein isothiocva-
nate- or phycoerythrin-conjugated goat-anti-mouse sec-
ondary antibodies. The specificity and optimal dilution of 
these antibodies were determined using donor spleno-
cvtes and the recipient's pretransplantation PBMC. Sin-
gle or two-color flow cvtometric methods were used to 
identify the donor cells and their lineage, respective Iv. 
Fiftv thousand events were acquired at each determina-
tion, and the frequency of donor cells less than O.S' 0 was 
considered below the reliable detection threshold. 
POLYMERASE CHAIN REACTION. In addition to the t10w 
cvtometric analvsis, polvrnerase chain reaction, as previ-
ouslv described [1, 3, 51, was used for detection 01 donor 
DNA in the recipient's PBMe. This method is more 
sensitive than the flow cvtometric technique: it can reli-
ablv detect one donor cell within 104 to lOS recipient cells 
Iii. Oligonucleotides for either the sex determinmg re-
gion of the Y chromosome or the appropriate mis-
matched HLA alleles were used as primers. 
Immune Monitoring 
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The in vitro immune status of the recipients, before and 
after transplantation. was assessed by the proliferative 
response of their PBMC to mitogens (concanavalin A. 
phytohemagglutinin), and recall antigens (tetanus tox-
oid) by mixed l\'mphocyte reactions (MLR) and by cell-
mediated Ivmphocvtotoxicitv assavs. The MLR cultures 
were carried out using 'Y-irradiated donor splenocytes 
and third-partv PBMC as stimulators (5 x 104 cells), and 
recipient PBMC as responders (5 X 104 cells). The cells 
were cultured at 3iOC for 6 davs in 5·/0 Cl~ in air. 
eH)-thymidine (1 ILCil was add~d to each weil at the 
beginning of the final 20 hours, and its degree of incor-
poration was determined by liquid scintillation counting. 
For cell-mediated lvmphocytotoxicitv assays, phytohe-
mogglutinin-activated 51 Cr-labeled donor splenocvtes 
and third-party PBMC were used as targets to eval~ate 
the effector function of 5- to 6-day MLR-cultured recipi-
ent's PBMe. Various effector:target ratios ranging from 
10:1 to 40:1 were used. 
Results 
Clinical Course 
BONE MARROW AUGMENTED PATIENTS. The infusion of do-
nor bone marrow was well tolerated. None of the 15 
recipients had graft-versus-host disease or complications 
related to the infusion of donor bone marrow. All pa-
tients, except 1. are alive with good allograft function 
(Table 1). The single death occurred in a heart recipient 
(patient 5) who died at home of a pulmonary embolus on 
POD 267. One week before his death, a routine right 
heart catheterization revealed normal cardiac function. 
At autopsy, there was no evidence of acute or chronic 
rejection in the transplanted heart (Fig 1). In 1 heart 
recipient (patient 10), who had been receiving aspirin 
preoperativel\', a duodenal perforation developed on 
POD 3. In another heart recipient (patient 1), a benign 
duodenal ulcer developed on POD 23i that was success-
fully treated, whereas an additional heart recipient (pa-
tient 8) had Acinetobacter sepsis from a pneumonia on 
POD 92, which resolved after appropriate therapy. 
Furthermore, two single-lung recipients (patients 14 
and 15), who received an allograft from the same donor, 
suffered moderate to severe primary graft dvsfunction 
(preservation injurY). which in 1 (patient 14) necessitated 
.;upport with an extra corporeal membrane oxygenator 
tor 3 days. Two other lung recipients had Candida albicans 
in bronchoalveolar lavage on POD 13i and 221 respec-
tivelv. and 1 hadARpergillusfumi~atus (patient 13) on POD 
58. All were successfully treated. 
CONTROLS. Heart or lung recipients for whom bone mar-
row was not available, due to our inability to obtain 
permission to retrieve cadaveric vertebral bodies, were 
used as contemporaneous controls. All 4 heart recipients 
are alive with good graft function, whereas the single 
lung recipient (patient 20) died on POD 104 due to 
complications related to preservation injury. This lung 
recipient required perioperative support with an extra-
.-\nn Thorac Surl!; 
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T<,ble 1. Outcome of Heart and Lun,? Recipients Rcceil'inl( Donor-Specific Bone Marrow Infusion 
Graft Function Immunosuppression 
Patient FYC FEV,· FK506 Pred Aza 
\10. Gratt roo Status LVEP III III fm~/davF (mg/dav/ Imgldav) Complication' Rejection· GvHD 
Heart 303 Alive \10 H 10 0 Duodenal ulcer (237) None None 
:: Heart 303 .-'<live \10 10 3 0 None None None 
3 Heart 27-1 Alive 0.88 (14) 1:1 10 100 None None None 
.. Heart 2i-l Alive O.iO (14) . .. 18 15 100 None None None 
3 Heart 267 Dead 0.66 (25) Pulmonary embolus (267) 3A (13) None 
6 Heart 262 Alive 0.55(11) 28 3 50 None 3A (15) None 
7 Heart 2-l0 Alive 0.73 (25) (, 10 0 None None None 
8 Heart 199 Alive 0.85 (10) 6 10 0 Gram-negative sepsis (92) None None 
9 Heart 30 Alive NO 36 20 0 None 3A (40) None 
10 Heart -+4 Alive \10 12 15 0 Duodenal perioration (3) 3A (24) None 
11 SL 227 Alive 1.i6 1.29 (191) 6 5 0 Candida albicans (137) None None 
12 SL 227 Alive 2.59 1.85 (191) ::0 10 0 Candida albicans (221) AR U (8) None 
13 DL 87 Alive 1.95 1.65 (51) :: 5 0 Aspergillus fumigatus (58) None None 
1-1 SL 59 Alive \10 \10 8 20 0 Preservation injury (1) AR m (32) None 
15 SL 39 Alive 1.-l 0.81 (28) 10 20 0 Preservation injury (1) AR m (11) None 
.• ~umbers in parentheses are postoperative dav. 
Aza = azathiopnne; DL = double lunsr;; FEV. = iorced exp,ratorY volume in the first second; FVC = forced vital capacity; GvHD - graft 
versus host disease; L VEF = let! ventncular electIOn iTactlon; \I D = not done: POD = postoperative day; !'red '"' predniaone: Sl = 
single lung. 
corporeal membrane oxvgenator because ot primary 
gralt failure. 
Rejection 
In the 10 heart-bone marrow recipients, the rate of 
rejection tgrade ~ 3A [9]) during the first 100 davs alter 
transplantation was 0.5 episodes, as compared with 1.0 
(p = 0.2i bv Fisher'S exact test) in a histoncal control 
group ot 26 heart recipients. who receIved an identical 
immunosuppressive regimen without bone marrow infu-
sion. Onlv 1 heart recipient (patient 3). who did not 
receive steroid induction during the penoperative period 
FiO{ 1. HistOl,<utrolu'(li or 1111 l'ndomlloc<lnlial bioV511 spenmen Of a 
;'"n" ",aml!!' 11'''/ IrcarT tTansviant rt'Clplrnt obtained after death at 
26i ./,lllS dTT,'" tranSl,iantatlVn. fill.,." 11'<15 110 (t·i/ular mri/tralion. 
'w{'{t'Stln,? tit"r tire .i .. <lth (It tlris patient was due to ""nlmmunologic 
, ,Iuses. AltllOu'(tr tire n;aCf (,lUSt' ot death is snll unknown. u r<,la-
tlVelli 11f~tD t/rromboemtlOlus III tire plI/monarv arterv was detected at 
,iUroVSll. I" oW /retort' 51'!'" "'!luctlOn.) 
(no steroid recycle during the first 5 postoperative days), 
had steroid-resistant rejection that required a 5-day 
course of 0KT3 for its resolution. Furthermore, 3 addi-
tional heart recipients required azathioprine because of 
persistent low-grade (:s grade 2) rejection and high 
serum creatinine levels that precluded the use of thera-
peutic doses of tacrolimus. Of the 5 lung-bone marrow 
recipients, 3 had mild to moderate rejection (grade > II 
[lOll on POD 11, 32, and 53 respectively, whereas 2 had a 
rejection-free postoperative course. 
DonOT Chimerism 
Detection of donor cells was feasible in all bone marrow-
augmented and nonaugmented patients by either flow 
cytometry or polymerase chain reaction. Control patients 
had no evidence of donor-cell chimerism in their PBMC 
at the most recent sample tested (Table 2), On the 
contrary, 11115 study patients (73%) exhibited stable 
donor cell chimerism for up to 220 days after transplan-
tation. It must be emphasized. however, that bone mar-
row-augmented recipients who were negative by poly-
merase chain reaction for donor cell chimerism in the last 
sample tested were positive in all previous analyses. 
In Vitro Immune Testing 
The unavailability of donor splenocytes precluded in 
vitro immune monitoring in 8115 (53%) of bone marrow-
augmented recipients. None of the bone marrow-
augmented (n = 7) or nonaugmented (n = 4) patients in 
whom testing was feasible exhibited any evidence ot 
donor-specific immune modulation (by MLR) for up to 
210 days after transplantation (Table 3). It is nevertheless 
noteworthy that there was a trend in the bone marrow-
augmented recipients toward a lower response to donor 
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Table 2. Detection of Donor Leukocytes in Recipient's Peripheral Blood Monocytes by Flow Cytometry and Polymerase Chain 
Reaction 
Patient 
No. 
1 
2 
3 
6 
4 
5 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Graft 
Heart 
Heart 
Heart 
Heart 
Heart 
Heart 
Heart 
Heart 
Heart 
Heart 
SL 
SL 
OL 
SL 
SL 
Heart 
Heart 
Heart 
Heart 
SL 
Bone Marrow 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
No 
No 
POO 
7-15 
"IF 
~c 
NF 
",,'F 
0.7 
2.7 
1.3 
1.7 
1.0 
0.8 
1.3 
1.-4 
2.7 
1.1 
1.7 
<0.5 
NO 
~1F 
NO 
2.8 
POO 
20-35 
"IF 
NF 
"IF 
"IF 
1.8 
1.1 
0.7 
1.2 
0.8 
ND 
2.8 
1.6 
1.3 
1.5 
1.5 
ND 
NO 
0.5 
NO 
<0.5 
Flow Cvtometn'" 
POO 
50-70 
NF 
NF 
NF 
NF 
<0.5 
2.1 
0.8 
1.2 
NO 
NO 
1.7 
1.5 
0.8 
0.9 
NO 
NO 
<0.5 
<0.5 
NO 
NO 
POO 
105-135 
NF 
NF 
NF 
NF 
<0.5 
NO 
0.9 
0.8 
NO 
NO 
2.1 
0.9 
NO 
NO 
NO 
NO 
NO 
NO 
<0.5 
NO 
POO 
150-220 
NF 
NF 
NF 
NF 
<0.5 
6.3 
1.0 
ND 
NO 
NO 
1.1 
0.7 
NO 
NO 
ND 
NO 
ND 
<0.5 
<0.5 
NO 
PCR 
(POD) 
- (239) 
... (302) 
- (225) 
- (220) 
... (274) 
+ (246) 
+ (199) 
+ (109) 
.... (11) 
+ (35) 
... (183) 
- (185) 
+ (66) 
... (36) 
+ (36) 
NO 
- (107) 
- (231) 
- (205) 
- (36) 
• Expressed as percent of donor cells detected in peripheral blood monocvtes or the recipIent. 
DL = double lung; !'lID = not done either due to short iollow-up or lack 01 adequate \'olume of sample; NF = not feasible; POD = 
postoperative day; SL = single lung. 
as compared with third party alloantigens when tested 
serially during the first 6 months after transplantation. 
Comment 
The use of bone marrow-derived cells (splenocvtes) to 
achieve donor-specific transplantation tolerance in neo-
natal mice was first reported by Billingham and associ-
ates [II]. Subsequently, chimerism with donor-specific 
transplantation tolerance was achieved in adult animal 
models bv preconditioning the host with diJIerent regi-
mens, which have included, among others, total body 
irradiation [12], total lymphoid irradiation [13], and the 
use of antilvmphocyte globulin [14]. 
The clinical use of donor bone marrow to prolong the 
survival of organ allografts was first attempted in kidney 
Table 3. Mixed LymphoCllte Response of Recipient's Lllmphocytes Against Donor and Third-Party Splenocytes" 
Patient 
"Jo. 
3 
8 
\olean 
SO 
Bone 
Graft Marrow 
Heart Yes 
Heart Yes 
Heart Yes 
Heart Yes 
Heart Yes 
Heart Yes 
Heart Yes 
, Counts per minute t x 1t}'1. 
Before 
Transplantation 
o 
86.7 
87.9 
36.1 
34.5 
21.8 
92.0 
44.8 
O/TP 
TP (',) 
137.9 63.0 
88.8 99.0 
34.2 105.0 
63.6 54.0 
9.3 234.0 
62.6 147.0 
27.7 162.0 
12.3.4 
02.8 
o 
ND 
83.4 
18.0 
22.1 
68.7 
12.4 
27 ... 
15-60 
TP 
NO 
49.7 
3 .. .5 
29.2 
18.0 
1·t2 
Postoperative Day 
70-120 
O/TP 
(",,) D TP 
.'\0 37.6 61.5 
168.0 13.6 2.3 
52.0 30.6 30.9 
76.0 '-.;0 NO 
381.0 .. 9.2 19.7 
~UKM 45.5 .. 9.7 
121.0 H7 64.5 
1 .. 7.7 
121.2 
D/TP 
("!o) 
61.0 
598.0 
99.0 
ND 
250.0 
91.0 
68.0 
194.5 
209.5 
D = donor cells; NO - not done; SO = s~ndard deVlanon: TP = third-pam. 
130-240 
o TP 
20.4 53.5 
118.2 88.1 
69.1 75.4 
1.6 .t2 
24.0 18.1 
25.3 37.3 
NO "JD 
O/TP 
(%) 
38.0 
134.0 
92.0 
37.0 
133.0 
68.0 
ND 
83.7 
43.7 
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transplant recIpients. Monaco and associates 1131 first 
reported the use ot antilymphocyte globulin and delaved 
(25 davs atter organ transplantationl donor bone marrow 
infusion in a kidney transplant recipient. The patient had 
no rejection during the postoperative follow-up until she 
died 8 months after transplantation of fatal pentonitis, 
secondary to perforated sigmoid diverticulitis. There was 
evidence ot donor red cell chimerism; however, it did not 
persist after the first month, and no white cell chimerism 
was detected for up to 21/2 months after transplantation. 
Barber and associates [161 used a similar regimen in 
recipients of cadaveric donor kidneys who were precon-
ditioned with antilymphocyte globulin, cvciosporine, 
azathioprine, and prednisone before adjuvant donor 
bone marrow infusion. Graft survival in the bone mar-
row-augmented patients was significantlv better than in 
contemporaneous controls, and other clin'ical evidence of 
benefit was also present, including a reduced need for 
immunosuppression and a lower incidence ot rejection in 
bone marrow-augmented chimeric recipients. Further-
more, donor cell chimerism was detected in PMM~I to 36% 
of patients 3 to 12 months after transplantation [171· 
However, using a similar approach, Rolles and col-
leagues [181 were unable to show anv distinct advantage 
that was atforded by delayed bone ~arrow transplanta-
tion to liver allograft recipients. 
In 1984, Kahn and co-workers [191 reported the com-
bined simultaneous infusion of donor bone marro\\' to 6 
heart transplant recipients who were preconditioned (7 
to 13 days earlier) with a total of 3,4 to 6.0 Gv ot total 
lvmphoid irradiation. Four patients died within '-; months 
of either primarv graft failure (n = 1), chronic rejection 
(n = 1)' or Intection In = 21. Furthermore. in the 2 patients 
who survived for 2 to -I years <ltter transplantation, 
donor-~peElfic hvporeactivitv Ibv \lLRl W<lS evidenced in 
1. whereas it was not tested'in the other 1191. The higher 
incidence llt infection in patients in this ~tudy" was 
,lttributed to <l combination of high dose of ~teroids and 
total lvmphoid irradiation. . 
These clinical studies were based on the premise that 
"space" needs to be created by rreconditionin~ or the 
host with c\'toreductive or cvtoablatiye therapv, thus 
.l!lowing tor engrattment of donor bone marrmv with 
subsequent establishment and perpetuation ot chimer-
ism. However. we ~nd others have recently demon-
strated that donor chimerism is J naturallv' occurnng 
phenomenon after transplantation or ~olid organs, in-
cludin~ the liver Ill, kidney 121, heart [31. . .lOd lung HI· 
This low level of donor cell chimerism was present in all 
long-term ~urviving kidnev [21 and liver III recipients. Its 
beneticial effects were most noticeable in lung allogratt 
recipients. In whom donor cell chimensm was aSSOCIated 
with .1 lower Incidence ot bronchiolitis obliterans [-II· 
These observ.1tions provided the toundation tor the ini-
tiation ot the current studv, in which unmodified MHC-
mIsmatched donor bone marrow cdls were intused into 
heart or lun~ recipients at the ttme ot organ placement 
WIthout ,lnv rreconditioninll; ot that host or deviation 
trom the routine dru~s and their therapeutic doses that 
PHAM ET AL 1019 
CHIMERISM IN HEART AND LUNG RECIPIENTS 
were required for maintenance of adequate immunosup-
pression. 
The preliminary data from this pilot study indicate that 
the infusion of unmodified donor bone marrow concur-
rentlv with heart or lung transplantation is safe, and is 
associated with an increased level of donor cell chimer-
ism. Furthermore, the early immunologic events after 
cardiac transplantation appear to have been altered bv 
the infusion of donor bone marrow. Although not stati;-
tically significant, there was a trend toward a lower 
incidence of rejection within the first 100 days after 
transplantation in the bone marrow-augmented heart 
recipients as compared with Similarly treated historical 
controls. However, there was no in vitro evidence of 
donor-specific hypo reactivity in the serial MLR analysis 
performed during the first 6 months after transplanta-
tion. 
Although the eventual effect of the augmented chimer-
ism remains speculative, it is conceivable that its pres-
ence would enhance the acceptance and survival of the 
graft and reduce the incidence of chronic rejection. 
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DISCUSSION 
DR BRUCE A. REITZ (Stanford. CAl: Doctor Pham should be 
congratulated for his presentation and Drs Griffith and Starzl for 
this very difficult clinical trial. They have demonstrated in their 
patients in these early results an increased incidence of micro-
chimerism when compared with concurrent controls, and their 
hypothesis is that this chimerism will result in better long-term 
acceptance of the gratt and perhaps a decrease in chronic 
rejection. Most previous work on bone marrow infusion at the 
time of transplantation has attempted to create donor-specific 
tolerance, perhaps an unacceptable or unobtainable clinical goal 
at the present time. but when bone marrow has been given it has 
usually been accompanied with some type of induction therapy, 
such as total lymphoid irradiation, whole body radiation, or 
antithymocyte globulin. My first question for Dr Pham is whv 
induction therapy was not used in these patients. Even antithy-
mocyte globulin alone would provide some induction. and 
antithymocyte globulin has been used as part of the lung 
transplant protocols at Pittsburgh in the past. 
Second, Dr Pham, can you comment on how vou might 
achieve a decrease in chronic rejection if there has been no 
significant decrease in the early rejection frequency or a signif-
icant increase in donor-specific hyporeactivity? I think vour data 
show trends in this regard but the manuscript clearlv shows that 
at this point there is no statistical dUference. 
Third, would you share with us some of the studies of FK 506 
and donor bone marrow infusion and how this combination 
compares with cyclosporine in terms of chimerism induction? 
Finally. the lack of gratt-versus-host disease is very encourag-
ing in this study. but I would give a word of caution in that in 
experiments that we have done with bone marrow intuslOn. the 
exact combination of accompanvmg immunosuppressIon IS ex-
tremelv important and minor changes can result in either 
hvpersensitivitv or. on the other hand, the induction 01 toler-
ance. So it is verY important to have a very specific protocol and 
to foUow it very close Iv. Doctor Pham. please comment on 
graft-versus-host disease In recipients of liver transplant and 
how those protocols might differ from vour heart protocoi. 
Again. congratulations on what is a very difficult clinical stud\". 
Ann Thorac pur~ 
1995;60:1015-20 
enhancement oi a human cadaver renal allograft with anti-
Iymphocvte serum (ALS) and donor bone marrow; case 
report ot an initial attempt. SurgerY 1976;79:384-92. 
16. Barber VVH. Mankin JA, Laskow DA, et aI. Long-term results 
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We look forward next vear or perhaps the vear after to getting 
the long-term iollow-up to see if your hypothesis has been 
validated. 
DR JOHN R. BENFIElD (Sacramento, CA): While Dr Ph am is 
coming to the microphone to respond to the questions. my sense 
of history allows me to comment that Dr David Blumenstock of 
Cooperstoym. :\Y. and Dr Thomas of bone marrow transplant 
fame investigated the concept of chimerism as an adjunct to 
lung transplantation in inbred beagles almost 30 vears ago. 
DR PHAM: Thank vou. Dr Reitz. for your comments. We did not 
use induction therapv such as antithvmocvte globulin or radia-
tion because we did not know what the antithvrnocvte globulin 
would do to the bone marrow stem cells. Doctor Barber and his 
associates from Birmingham, Alabama. had used antithymocyte 
globulin induction in their combined kidney-bone marrow trial 
and had observed an increase in the level of chimerism. How-
ever, their protocol was different from ours in that they had 
infused frozen bone marrow cells approximately 21 davs after 
the patient had receIved a kidnev transplant. \Ve did not use 
preoperative radiation because of our concern for subjecting the 
patients to a higher risk of graft-versus-host-disease. and be-
cause of the difficult logistics due to the time constraint. 
On vour question about chronic rejection. the onlv available 
data on chimensm and chronic rejection are those reported by 
nur group. We had shown that lung recipients with microchi-
merism had a lower risk of obliterative bronchiolitis develop-
ment. These data torm the basis lor the current mal. 
We have not used cvc!osporine in recipIents ot combined 
hone marrow and heart or lung transplants. To date. we have not 
seen gratt-versus-host disease in heart. lung. or kidnev recipi-
ents who received concurrent bone marrow infuSIOn. However. 
mild gratt-versus-host disease developed in 2 of the 28 liver-
bone marrow recipients. The graft-versus-host disease resolved 
~pontaneouslyD In 1. and with an increase in the prednisone dose 
from 7.S mgldav to 15 mg/dav in another. 
